Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?

dc.creatorVanaerschot, Manu
dc.creatorDumetz, Franck
dc.creatorRoy, Syamal
dc.creatorPonte-Sucre, Alicia
dc.creatorArevalo, Jorge
dc.creatorDujardin, Jean Claude
dc.date2014-06-07T23:56:35Z
dc.date2014-06-07T23:56:35Z
dc.date2014-06-07
dc.date.accessioned2022-10-28T00:59:17Z
dc.date.available2022-10-28T00:59:17Z
dc.identifier1478-7210
dc.identifierhttp://hdl.handle.net/10872/6540
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4940672
dc.descriptionTwo major leishmaniasis treatments have shown a significant decrease in effectiveness in the last few decades, mostly in the Indian subcontinent but also in other endemic areas. Drug resistance of Leishmania correlated only partially to treatment failure (TF) of pentavalent antimonials, and has so far proved not to be important for the increased miltefosine relapse rates observed in the Indian subcontinent. While other patient- or drug-related factors could also have played a role, recent studies identified several parasite features such as infectivity and host manipulation skills that might contribute to TF. This perspective aims to discuss how different parasitic features other than drug resistance can contribute to TF of leishmaniasis and how this may vary between different epidemiological contexts.
dc.descriptionEuropean Comision, Belgian Development Cooperation, Flemish Fund for Scientifi Research, Alexander von Humboldt Foundation, CDCH-Universidad Central de Venezuela
dc.languageen_US
dc.relationExpert Reviews Anti Infect Therapy;
dc.subjectdrug resistance
dc.subjectleishmania
dc.subjectleishmaniasis
dc.subjectmiltefosine
dc.subjectpentavalent antimonials
dc.subjecttreatment failure
dc.titleTreatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
dc.typePreprint


Este ítem pertenece a la siguiente institución